Abstract
[This corrects the article DOI: 10.3389/fonc.2019.00707.].
Highlights
Sonia Pernas 1*, Anna Petit 2, Fina Climent 2, Laia Paré 3, J
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way
Read more 
Summary
Introduction
Sonia Pernas 1*, Anna Petit 2, Fina Climent 2, Laia Paré 3, J. Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution Edited and reviewed by: Michael Gnant, Medical University of Vienna, Austria
Results
Conclusion
Sign-in/Register to view highlights & summary Full Text Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
